ADVERTISEMENT
Log in here to read the desired article.
ADVERTISEMENT
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2171 entries already.
Evotec SE is widening its 2022 R&D collaboration SynaptixBio Ltdi to optimise and identify new antisense oligonucleotides to treat children with H-ABC leukodystrophy, a rare genetic myelin synthesis defect that shows similar symptoms such as multiple sclerosis.
In view of her confirmation as EU Commission President, biotech associations have reminded Ursula von der Leyen of her promise to strategically promote the sector with an EU Biotech Act 2025.
Scientists at Hannover Medical School (MHH) have genetically engineered pig lungs in such a way that immunosuppressants could be reduced during transplants.
Czech Sotio Biotech has inked an R&D and licence option agreement with Chinese antibody maker Biocytogen.
Targeted protein degradation Draupnir Bio Aps has raised further €12m in an equitiy investment to advance its preclinical pipeline.
CordenPharma is making a record investment of about €900m over the next three years in expanding its peptide platform, both at its Colorado, US site and in Europe.
German cancer specialist Catalym GmbH has raised US$150m to finance proof-of-concept studies.
French Sensorion SA has reported new efficacy endpoints data from SENS-401 in a Phase II study for the preservation of residual hearing loss.
In the largest expansion in the company’s 150-year history, the Laupheim-headquartered CDMO Rentschler Biopharma SE has launched a new production line at its site in Milford, USA.
German iRhom2-targeted antibody specialist SciRhom GmbH has closed an oversubscribed €63m Series A financing that will be used to provide clinical proof of concept in autoimmune disorders.